SCHEMBL20265669

SCHEMBL20265669

NNc1nccn2cccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.40
HTR3A P46098 1/20 0.40
SRC P12931 1/20 0.36
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
MAOA P21397 1/20 0.33
PTGS1 P23219 1/20 0.33
OPRM1 P35372 1/20 0.33
KCNH2 Q12809 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAP4K4 O95819 4/20 0.33
NUDT1 P36639 1/20 0.32
ACKR3 P25106 1/20 0.32
GOT1 P17174 1/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 2/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20278386 0.81 MAP4K4 (0.51) CHRNA7HTR3ASRCALDH1A1MAP4K4
SCHEMBL397662 0.74 NUDT1 (0.50) CHRNA7HTR3AALDH1A1MAP4K4NUDT1
SCHEMBL20265548 0.73 MAP4K4 (0.40) ALDH1A1MAPTADORA3MAOAPTGS1
SCHEMBL20265413 0.71 NUDT1 (0.52) NUDT1
SCHEMBL3042386 0.69 KDM4E (0.33) CHRNA7HTR3AALDH1A1NUDT1ACKR3
SCHEMBL1154852 0.69 ACKR3 (0.33) CHRNA7HTR3AALDH1A1MAP4K4NUDT1
SCHEMBL8829202 0.69 KDM4E (0.41) CHRNA7HTR3ASRCALDH1A1MAP4K4
SCHEMBL9181834 0.69 KDM4E (0.33) CHRNA7HTR3AALDH1A1MAPTMAP4K4
SCHEMBL20265600 0.69 KDM4E (0.38) CHRNA7HTR3AALDH1A1MAPTACKR3
SCHEMBL20265108 0.68 MAP4K4 (0.69) CHRNA7HTR3AMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
EP-3558969-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2019-10-30 EP disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 CHRNA7 4700/4885HTR3A 3438/4885SRC 1643/4885
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 CHRNA7 4700/4885HTR3A 3438/4885SRC 1643/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 CHRNA7 4700/4885HTR3A 3438/4885SRC 1643/4885
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 CHRNA7 4700/4885HTR3A 3438/4885SRC 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.